Cargando…

State of the art in osteoporosis risk assessment and treatment

BACKGROUND: Osteoporosis constitutes a major public health problem, through its association with age-related fractures, particularly of the hip, vertebrae, distal forearm, and humerus. Over recent decades, it has evolved from being viewed as an inevitable consequence of ageing, to being recognised a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, J., Curtis, E. M., Cooper, C., Harvey, N. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751157/
https://www.ncbi.nlm.nih.gov/pubmed/30980341
http://dx.doi.org/10.1007/s40618-019-01041-6
_version_ 1783452561597005824
author Liu, J.
Curtis, E. M.
Cooper, C.
Harvey, N. C.
author_facet Liu, J.
Curtis, E. M.
Cooper, C.
Harvey, N. C.
author_sort Liu, J.
collection PubMed
description BACKGROUND: Osteoporosis constitutes a major public health problem, through its association with age-related fractures, particularly of the hip, vertebrae, distal forearm, and humerus. Over recent decades, it has evolved from being viewed as an inevitable consequence of ageing, to being recognised as a serious and eminently treatable disease. MATERIALS AND METHODS: In this article, we review the literature pertaining to the epidemiology of osteoporosis, associated health burden, approaches to risk assessment and treatment. RESULTS: Although there is some evidence that fracture incidence has reached a plateau, or even started to decline, in the developed world, an ageing population and adoption of westernised lifestyles in transitioning populations is leading to an increasing burden of osteoporosis across the world. Whilst the clinical definition of osteoporosis has been based solely on bone mineral density, the prediction of fracture at the individual level has been improved by consideration of clinical risk factors in tools such as FRAX(®), derived from a greater understanding of the epidemiology of osteoporosis. Such advances in approaches to primary and secondary prevention of fractures, coupled with elucidation of the underlying biology, and the development of a range of highly effective antiosteoporosis medications, have enabled a step change in our ability to prevent osteoporosis-related fractures. However, there remains a substantial disparity between the number of individuals at high fracture risk and number treated globally. CONCLUSION: Urgent work is needed at the level of health care systems, national and international policy, and in communication with patients and public, to ensure that all patients who should receive treatment for osteoporosis actually do so.
format Online
Article
Text
id pubmed-6751157
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-67511572019-10-04 State of the art in osteoporosis risk assessment and treatment Liu, J. Curtis, E. M. Cooper, C. Harvey, N. C. J Endocrinol Invest Review Article BACKGROUND: Osteoporosis constitutes a major public health problem, through its association with age-related fractures, particularly of the hip, vertebrae, distal forearm, and humerus. Over recent decades, it has evolved from being viewed as an inevitable consequence of ageing, to being recognised as a serious and eminently treatable disease. MATERIALS AND METHODS: In this article, we review the literature pertaining to the epidemiology of osteoporosis, associated health burden, approaches to risk assessment and treatment. RESULTS: Although there is some evidence that fracture incidence has reached a plateau, or even started to decline, in the developed world, an ageing population and adoption of westernised lifestyles in transitioning populations is leading to an increasing burden of osteoporosis across the world. Whilst the clinical definition of osteoporosis has been based solely on bone mineral density, the prediction of fracture at the individual level has been improved by consideration of clinical risk factors in tools such as FRAX(®), derived from a greater understanding of the epidemiology of osteoporosis. Such advances in approaches to primary and secondary prevention of fractures, coupled with elucidation of the underlying biology, and the development of a range of highly effective antiosteoporosis medications, have enabled a step change in our ability to prevent osteoporosis-related fractures. However, there remains a substantial disparity between the number of individuals at high fracture risk and number treated globally. CONCLUSION: Urgent work is needed at the level of health care systems, national and international policy, and in communication with patients and public, to ensure that all patients who should receive treatment for osteoporosis actually do so. Springer International Publishing 2019-04-12 2019 /pmc/articles/PMC6751157/ /pubmed/30980341 http://dx.doi.org/10.1007/s40618-019-01041-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Liu, J.
Curtis, E. M.
Cooper, C.
Harvey, N. C.
State of the art in osteoporosis risk assessment and treatment
title State of the art in osteoporosis risk assessment and treatment
title_full State of the art in osteoporosis risk assessment and treatment
title_fullStr State of the art in osteoporosis risk assessment and treatment
title_full_unstemmed State of the art in osteoporosis risk assessment and treatment
title_short State of the art in osteoporosis risk assessment and treatment
title_sort state of the art in osteoporosis risk assessment and treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751157/
https://www.ncbi.nlm.nih.gov/pubmed/30980341
http://dx.doi.org/10.1007/s40618-019-01041-6
work_keys_str_mv AT liuj stateoftheartinosteoporosisriskassessmentandtreatment
AT curtisem stateoftheartinosteoporosisriskassessmentandtreatment
AT cooperc stateoftheartinosteoporosisriskassessmentandtreatment
AT harveync stateoftheartinosteoporosisriskassessmentandtreatment